Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
Zhou J. et al, (2025), EClinicalMedicine
A Mendelian randomisation study of the effect of body mass index on 52 causes of death among 125 000 Mexican adults with admixed ancestry
Gnatiuc Friedrichs L. et al, (2025), International Journal of Epidemiology
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression
Greene T. et al, (2025), Clinical Journal of the American Society of Nephrology, 20, 632 - 641
Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings.
Marx N. et al, (2025), Eur Heart J Qual Care Clin Outcomes
An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression
Donovan KILLIAN. et al, (2025), European Journal of Human Genetics
Type 2 diabetes and cause-specific mortality in Mexico City: a Mendelian randomisation analysis
EMBERSON J. et al, (2025), The Lancet Regional Health - Americas
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline.
Madero M. et al, (2025), Ann Intern Med
The Prevention and Management of Chronic Kidney Disease among Patients with Metabolic Syndrome
ZHU D. et al, (2024), Kidney International
Abstract 4113475: Association of Age at Diabetes Diagnosis and All-cause and Cardiovascular Mortality among 600,000 US Adults
Thomson B. et al, (2024), Circulation, 150, a4113475 - a4113475
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.
Zhu D. and Herrington WG., (2024), Ann Intern Med
In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
Zhu D. and Herrington WG., (2024), Ann Intern Med
Alcohol and mortality in Mexico: prospective study of 150 000 adults.
Trichia E. et al, (2024), Lancet Public Health, 9, e907 - e915
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
ZHU D. et al, (2024), NDT International
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
Herrington WG. and Haynes R., (2024), N Engl J Med, 391, 178 - 179
Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study.
Collister D. et al, (2024), Nephrol Dial Transplant
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal